Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates
Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates is a paper indexed in PICO Portal from OpenAlex.
How many citations does Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates have?
Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates has 130 citations in the OpenAlex counts PICO Portal stores.
When was Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates published?
Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates has 2014 year in the PICO Portal index.
What is the open-access status of Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates?
Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates has bronze oa status in the PICO Portal index.
What is the DOI of Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates?
The DOI for Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates is on the source record.
What is the PMID of Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates?
The PMID for Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates is on the source record.
What is the OpenAlex record for Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates?
The OpenAlex for Sequential combination therapy of ovarian cancer with degradable <i>N</i> -(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates is on the source record.